Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 182-193 http://medscipublisher.com/index.php/cge 191 Alzhrani R., Alsaab H., Petrovici A., Bhise K., Vanamala K., Sau S., Krinock M., and Iyer A., 2020, Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems, Drug Discovery Today, 25(4): 718-730. https://doi.org/10.1016/j.drudis.2019.11.006 Bobbin M.L., and Rossi J.J., 2016, RNA interference (RNAi)-based therapeutics: delivering on the promise?, Annual Review of Pharmacology and Toxicology, 56(1): 103-122. https://doi.org/10.1146/annurev-pharmtox-010715-103633 Bruyère D., Roncarati P., Lebeau A., Lerho T., Poulain F., Hendrick E., Pilard C., Reynders C., Ancion M., Luyckx M., Renard M., Jacob Y., Twizere J., Peiffer R., Peulen O., Delvenne P., Hubert P., McBride A., Gillet N., Masson M., and Herfs M., 2023, Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair, Theranostics, 13(3): 1130. https://doi.org/10.7150/thno.78091 Chalbatani G., Dana H., Gharagouzloo E., Grijalvo S., Eritja R., Logsdon C., Memari F., Miri S., Rad M., and Marmari V., 2019, Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach, International Journal of Nanomedicine, 3111-3128. https://doi.org/10.2147/IJN.S200253 Chen M., Dong C., and Shi S., 2021, Nanoparticle‐mediated siRNA delivery and multifunctional modification strategies for effective cancer therapy, Advanced Materials Technologies, 6(10): 2001236. https://doi.org/10.1002/admt.202001236 Chen X., Mangala L., Rodríguez-Aguayo C., Kong X., Lopez-Berestein G., and Sood A., 2018, RNA interference-based therapy and its delivery systems, Cancer and Metastasis Reviews, 37: 107-124. https://doi.org/10.1007/s10555-017-9717-6 Chen Y., Jiang H., Wang T., He D., Tian R., Cui Z., Tian X., Gao Q., Ma X., Yang J., Wu J., Tan S., Xu H., Tang X., Wang Y., Yu Z., Han H., Das B., Severinov K., Hitzeroth I., Debata P., Xu W., Fan W., Jin Z., Cao C., Yu M., Xie W., Huang Z., Hu Z., and You Z., 2020, In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system, Antiviral Research, 178: 104794. https://doi.org/10.1016/j.antiviral.2020.104794 Davis M., Zuckerman J., Choi C., Seligson D., Tolcher A., Alabi C., Yen Y., Heidel J., and Ribas A., 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 464(7291): 1067-1070. https://doi.org/10.1038/nature08956 Deng Y., Wang C., Choy K., Du Q., Chen J., Wang Q., Li L., Chung T., and Tang T., 2014, Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies, Gene, 538(2): 217-227. https://doi.org/10.1016/j.gene.2013.12.019 DiPaolo J.A., and Alvarez-Salas L.M., 2004, Advances in the development of therapeutic nucleic acids against cervical cancer, Expert Opinion on Biological Therapy, 4(8): 1251-1264. https://doi.org/10.1517/14712598.4.8.1251 Elbashir S.M., Lendeckel W., and Tuschl T., 2001, RNA interference is mediated by 21-and 22-nucleotide RNAs, Genes and Development, 15(2): 188-200. https://doi.org/10.1101/gad.862301 Estêvão D., Costa N.R., da Costa R.M.G., and Medeiros R., 2019, Hallmarks of HPV carcinogenesis: the role of E6, E7 and E5 oncoproteins in cellular malignancy, Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms, 1862(2): 153-162. https://doi.org/10.1016/j.bbagrm.2019.01.001 Gangopadhyay S., Nikam R.R., and Gore K.R., 2021, Folate receptor-mediated siRNA delivery: recent developments and future directions for RNAi therapeutics, Nucleic Acid Therapeutics, 31(4): 245-270. https://doi.org/10.1089/nat.2020.0882 Gomes-da-Silva L.C., Fonseca N.A., Moura V., Pedroso de Lima M.C., Simões S., and Moreira J.N., 2012, Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges, Accounts of Chemical Research, 45(7): 1163-1171. https://doi.org/10.1021/ar300048p Hoppe-Seyler K., Bossler F., Braun J.A., Herrmann A.L., and Hoppe-Seyler F., 2018, The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets, Trends in Microbiology, 26(2): 158-168. https://doi.org/10.1016/j.tim.2017.07.007 Hu B., Zhong L., Weng Y., Peng L., Huang Y., Zhao Y., and Liang X.J., 2020, Therapeutic siRNA: state of the art, Signal Transduction and Targeted Therapy, 5(1): 101. https://doi.org/10.1038/s41392-020-0207-x Jonson A.L., Rogers L.M., Ramakrishnan S., and Downs Jr L.S., 2008, Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer, Gynecologic Oncology, 111(2): 356-364. https://doi.org/10.1016/j.ygyno.2008.06.033 Jung H.S., Rajasekaran N., Ju W., and Shin Y.K., 2015, Human papillomavirus: current and future RNAi therapeutic strategies for cervical cancer, Journal of Clinical Medicine, 4(5): 1126-1155. https://doi.org/10.3390/jcm4051126 Kenny G., Kamaly N., Kalber T., Brody L., Sahuri M., Shamsaei E., Miller A., and Bell J., 2011, Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo, Journal of Controlled Release, 149(2): 111-116. https://doi.org/10.1016/j.jconrel.2010.09.020
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==